Kimberly J. Popovits Sells 10,000 Shares of Genomic Health, Inc. (NASDAQ:GHDX) Stock

Genomic Health, Inc. (NASDAQ:GHDX) CEO Kimberly J. Popovits sold 10,000 shares of the firm’s stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $72.53, for a total value of $725,300.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Kimberly J. Popovits also recently made the following trade(s):

  • On Monday, August 12th, Kimberly J. Popovits sold 25,000 shares of Genomic Health stock. The shares were sold at an average price of $73.31, for a total value of $1,832,750.00.
  • On Thursday, August 8th, Kimberly J. Popovits sold 25,000 shares of Genomic Health stock. The stock was sold at an average price of $73.85, for a total value of $1,846,250.00.
  • On Friday, August 9th, Kimberly J. Popovits sold 50,000 shares of Genomic Health stock. The stock was sold at an average price of $73.76, for a total transaction of $3,688,000.00.

Shares of GHDX stock traded up $0.37 during trading hours on Wednesday, reaching $72.98. The company had a trading volume of 316,158 shares, compared to its average volume of 557,530. The company has a debt-to-equity ratio of 0.17, a quick ratio of 5.74 and a current ratio of 5.74. Genomic Health, Inc. has a twelve month low of $50.77 and a twelve month high of $92.18. The company has a market capitalization of $2.68 billion, a P/E ratio of 69.50 and a beta of 1.00. The stock’s fifty day simple moving average is $72.85 and its 200 day simple moving average is $65.22.

Genomic Health (NASDAQ:GHDX) last released its quarterly earnings results on Monday, July 29th. The medical research company reported $0.42 EPS for the quarter, topping the consensus estimate of $0.35 by $0.07. The firm had revenue of $114.14 million for the quarter, compared to analyst estimates of $110.78 million. Genomic Health had a return on equity of 19.51% and a net margin of 11.69%. Genomic Health’s revenue for the quarter was up 19.4% on a year-over-year basis. During the same period in the previous year, the company posted $0.23 EPS. As a group, equities analysts expect that Genomic Health, Inc. will post 1.51 earnings per share for the current year.

Several research analysts recently commented on GHDX shares. Deutsche Bank cut their price target on shares of Genomic Health from $80.00 to $55.00 and set a “hold” rating on the stock in a report on Thursday, May 30th. Needham & Company LLC downgraded shares of Genomic Health from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 30th. JPMorgan Chase & Co. raised shares of Genomic Health from an “underweight” rating to a “neutral” rating and increased their price objective for the stock from $60.00 to $72.00 in a research report on Monday, July 29th. Piper Jaffray Companies downgraded shares of Genomic Health from an “overweight” rating to a “neutral” rating in a research note on Monday, July 29th. Finally, Barclays raised shares of Genomic Health from an “underweight” rating to an “equal weight” rating and raised their target price for the company from $45.00 to $72.00 in a research note on Tuesday, July 30th. Ten analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average price target of $69.86.

A number of large investors have recently modified their holdings of the business. Jennison Associates LLC boosted its position in Genomic Health by 5.7% in the 2nd quarter. Jennison Associates LLC now owns 13,726 shares of the medical research company’s stock valued at $798,000 after buying an additional 738 shares during the last quarter. Acadian Asset Management LLC increased its stake in shares of Genomic Health by 16.2% in the second quarter. Acadian Asset Management LLC now owns 1,037,652 shares of the medical research company’s stock worth $60,358,000 after buying an additional 144,538 shares during the last quarter. OppenheimerFunds Inc. increased its stake in shares of Genomic Health by 30.0% in the first quarter. OppenheimerFunds Inc. now owns 469,560 shares of the medical research company’s stock worth $32,893,000 after buying an additional 108,337 shares during the last quarter. Atria Investments LLC acquired a new stake in Genomic Health in the second quarter valued at $1,416,000. Finally, BNP Paribas Arbitrage SA boosted its stake in Genomic Health by 687.8% during the 1st quarter. BNP Paribas Arbitrage SA now owns 4,892 shares of the medical research company’s stock valued at $343,000 after acquiring an additional 4,271 shares during the last quarter. 95.36% of the stock is owned by institutional investors.

Genomic Health Company Profile

Genomic Health, Inc, a healthcare company, provides clinically actionable genomic information to personalize cancer treatment decisions in the United States and internationally. The company develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, which allows physicians and patients to make individualized treatment decisions.

Recommended Story: How does a reverse stock split work?

Insider Buying and Selling by Quarter for Genomic Health (NASDAQ:GHDX)

Receive News & Ratings for Genomic Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health and related companies with MarketBeat.com's FREE daily email newsletter.